Transformed streptomyces bacteria and method for producing bialaphos and / or l-glufosinate
By disrupting or suppressing genes in the labendiol and actinoallolide A synthesis clusters, the production of bialaphos and L-glufosinate in Streptomyces bacteria is enhanced, addressing inefficiencies in existing methods and improving fermentation yields.
Patent Information
- Application Number
- JP2023074004
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-04-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods for producing bialaphos and L-glufosinate, which are microbial herbicides, are not efficient enough to meet the demand for environmentally friendly and cost-effective alternatives to chemically synthesized pesticides.
Disrupting or suppressing specific genes in the labendiol and actinoallolide A synthesis gene clusters in Streptomyces bacteria to enhance the metabolic flux towards bialaphos and L-glufosinate production, utilizing genetic engineering techniques to modify the bacterial strains.
The modified Streptomyces bacteria exhibit enhanced production of bialaphos and L-glufosinate, achieving higher yields compared to unmodified strains, facilitating efficient fermentation processes.
Smart Images

Figure 2024158647000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates generally to the microbial industry, and in particular to a Streptomyces bacterium in which production of bialaphos and / or L-glufosinate is enhanced by, for example, disrupting a gene in a specific secondary metabolite synthesis gene cluster, and a method for producing bialaphos and / or L-glufosinate. [Background technology]
[0002] In general, chemically synthesized pesticides are widely used as herbicides because they are stable, highly effective, and cost-effective. However, in recent years, from the viewpoint of environmental load, there is an increasing demand for herbicides derived from microbial metabolites to replace chemically synthesized pesticides. Herbicides derived from microbial metabolites are natural products, and therefore generally have the advantages of being highly biodegradable and having low environmental load.
[0003] Known herbicides derived from microbial metabolites include the amino acid herbicide bialaphos. Bialaphos is a herbicide derived from Streptomyces ( Streptomyces It is a secondary metabolite produced by actinomycetes belonging to the genus Streptomyces, e.g., Streptomyces hygroscopicus ( Streptomyces hygroscopicus It has been reported that bialaphos can be produced by the method of fermentation (Non-Patent Document 1). It has also been reported that the productivity of bialaphos has been improved by mutation breeding (Non-Patent Document 2).
[0004] In addition, Streptomyces hygroscopicus and Streptomyces viridochromogenes ( Streptomyces viridochromogenes ) Analysis of the bialaphos synthase gene cluster is currently underway (Non-Patent Documents 3 and 4). [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Tachibana K. et al., 1986, Journal of the Pesticide Science Society of Japan, 11, 297-304 [Non-Patent Document 2] Takebe et al., 1995, Journal of Bioengineering, 73, 413-24 [Non-Patent Document 3] Schwartz D. et al., 2004, Applied and Environmental Microbiology, 70, 7093-7102 [Non-Patent Document 4] Joshua A. V Blodgett et al. 2016, J Antibiot (Tokyo). 69, 15-25 Summary of the Invention [Problem to be solved by the invention]
[0006] An objective of the present invention is to provide a transformed Streptomyces bacterium having improved ability to produce bialaphos and / or L-glufosinate, and a method for producing bialaphos and / or L-glufosinate using the transformed Streptomyces bacterium. [Means for solving the problem]
[0007] As a result of intensive research conducted by the present inventors to solve the above problems, it was revealed that Streptomyces bacteria have many gene clusters related to secondary metabolite synthesis pathways in addition to the bialaphos synthesis gene cluster. Based on the knowledge that the bacterium can produce secondary metabolites other than bialaphos, the present inventors found that the productivity of bialaphos and L-glufosinate can be improved by suppressing the production of specific secondary metabolites other than bialaphos and modifying the metabolic flux to be toward bialaphos synthesis, thereby completing the present invention.
[0008] The present invention provides the following: [1] Streptomyces ( Streptomyces ) bacteria, A bacterium in which production of bialaphos and / or L-glufosinate is enhanced by disrupting one or more genes contained in the lavendiol synthesis gene cluster or the actinoallolide A synthesis gene cluster, or by suppressing the expression of the genes. [2] The bacterium described in [1], wherein the one or more genes include a gene encoding a polyketide synthase. [3] The bacterium described in [1], wherein the one or more genes include the following polynucleotides (a) and / or (b): (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 or a polynucleotide having a nucleotide sequence which hybridizes under stringent conditions with its complementary sequence and encodes a protein having polyketide synthase activity; (b) a polynucleotide having a nucleotide sequence of SEQ ID NO: 2 or a polynucleotide having a nucleotide sequence that hybridizes under stringent conditions with its complementary sequence and encodes a protein having polyketide synthase activity; [4] Streptomyces viridochromogenes ( Streptomyces viridochromogenes ) or Streptomyces hygroscopicus ( Streptomyces hygroscopicus The bacterium according to any one of [1] to [3], which is a bacterium belonging to the Bacillus subtilis. [5] A method for producing bialaphos and / or L-glufosinate, comprising the steps of: A production method comprising culturing the bacterium according to any one of [1] to [4] in a culture medium to produce and accumulate bialaphos and / or L-glufosinate in the culture medium and / or the bacterial cells. Effect of the Invention
[0009] According to the present invention, by using a Streptomyces bacterium in which a gene in a specific secondary metabolite synthesis gene cluster has been disrupted or the expression of the gene has been suppressed, bialaphos and / or L-glufosinate can be efficiently produced by fermentation. [Brief description of the drawings]
[0010]
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
[0011] In this specification, the strains with accession numbers beginning with the word JCM are registered with the Japan Collection of Microorganisms (RIKEN BioResource Center, Microbial Materials Research Center). Microorganisms stored in the Laboratory of Microorganisms (Hokkaido University, Tsukuba City, Ibaraki Prefecture, Japan, Postal Code: 305-0074, Address: 3-1-1 Takanodai, Tsukuba City, Ibaraki Prefecture) The number is assigned to the organization and is available from the organization.
[0012] As used herein, strains having accession numbers beginning with the word ATCC can be obtained from the American Type Culture Collection (Address: 10801 University Boulevard Manassas, VA 20110, United States of America).
[0013] In this specification, the strains with accession numbers beginning with the words NBRC are registered trademarks of the National Institute of Technology and Evaluation (NITE) (Postal Code: 292-0818, Address: 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan). This is a number given to microorganisms stored in the National Institute of Informatics (NII) and can be obtained from the Institute.
[0014] In this specification, the strains having accession numbers beginning with the word DSM are registered with the Deutsche Sammlung von This is the number assigned to the microorganisms stored at Mikroorganismen und Zellkulturen GmbH (Inhoffenstr. 7B 38124 Braunschweig Germany) and can be obtained from the institution.
[0015] <1> The Streptomyces of the present invention Streptomyces ) genus bacteria The Streptomyces bacterium of the present invention may be any bacterium belonging to the genus Streptomyces, so long as one or more genes contained in the lavendiol synthesis gene cluster or the actinoallolide A synthesis gene cluster are disrupted or expression of the genes is suppressed, and production of bialaphos and / or L-glufosinate is enhanced.
[0016] Streptomyces bacteria may inherently have the ability to produce bialaphos and / or L-glufosinate (e.g., Non-Patent Documents 1 and 2), or may be produced by mutation or DNA recombination. The bacterium of the present invention may be one that has been modified to have the ability to produce bialaphos and / or L-glufosinate using a recombinant technology. The bacterium of the present invention can be obtained by disrupting one or more genes contained in the lavendiol synthesis gene cluster or the actinoallolide A synthesis gene cluster or suppressing the expression of the genes in a Streptomyces bacterium that inherently has the ability to produce bialaphos and / or L-glufosinate, or in a Streptomyces bacterium that has been imparted with the ability to produce bialaphos and / or L-glufosinate, thereby enhancing the production of bialaphos and / or L-glufosinate.
[0017] The term "ability to produce bialaphos and / or L-glufosinate" may refer to the ability of a Streptomyces bacterium to produce and accumulate bialaphos and / or L-glufosinate in a culture medium and / or in the bacterial cells to an extent that the bialaphos and / or L-glufosinate can be recovered from the medium and / or the bacterial cells when the bacterium is cultured in the culture medium.
[0018] "Bialaphos" is also known as phosphinothricin tripeptide (PTT) and is a phosphinothricin (PT) compound consisting of two molecules of L-alanine and one molecule of the amino acid. Bialaphos has the following chemical formula:
[0019] [ka]
[0020] The term "bialaphos" is not limited to the free form of bialaphos, but may also include its salts or hydrates, or adducts formed by bialaphos and other organic or inorganic compounds. That is, the term "bialaphos" may, for example, mean the free form of bialaphos or a hydrate or adduct of bialaphos. The term "bialaphos" may, for example, include salts such as sodium salt, potassium salt, ammonium salt, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride, and internal salts such as zwitterions of bialaphos acid.
[0021] "L-glufosinate" is a compound represented by the chemical formula below and is widely used as a pesticide. When two molecules of alanine are bound to L-glufosinate, it becomes bialaphos. Since L-glufosinate is a precursor of bialaphos, the bialaphos-producing bacteria also produce a certain amount of L-glufosinate. Therefore, the Streptomyces bacterium of the present invention can also be used to produce L-glufosinate. The term "L-glufosinate" may include, for example, salts such as sodium salt, potassium salt, ammonium salt, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride, and inner salts such as zwitterions.
[0022] [ka]
[0023] The Streptomyces bacterium of the present invention is not particularly limited, but may be, for example, Streptomyces viridochromogenes ( Streptomyces viridochromogenes ), a bacterium belonging to the group Streptomyces hygroscopicus ( Streptomyces hygroscopicus ), a bacterium belonging to the Streptomyces luridus ), a bacterium belonging to the family Streptomyces ruberomulinas ( Streptomyces rubellomurinus ) bacteria. Among these, bacteria belonging to Streptomyces viridochromogenes or Streptomyces hygroscopicus are preferred, and bacteria belonging to Streptomyces viridochromogenes are more preferred. These bacteria inherently have the ability to produce bialaphos and / or L-glufosinate, and are suitable as Streptomyces bacteria capable of producing bialaphos and / or L-glufosinate.
[0024] Examples of bacteria belonging to Streptomyces viridochromogenes include Streptomyces viridochromogenes JCM4977 strain, Tue57 strain (Weitnauer, G. et. al., (2002). Microbiology, 148(2), 373-379.), subsp. komabensis (ATCC29814 strain), and subsp. sulfomycini (NBRC13830) strain. Bacteria belonging to Streptomyces hygroscopicus include subsp. hygroscopicus (ATCC21589), subsp. ascomyceticus (ATCC14891), subsp. yingchengensis (Qin, Z. et al. (1994). J. Bacterial., 176(7), 2090-2095.), subsp. limoneus (ATCC21431), subsp. duamyceticus (JCM4427), subsp. enhygrus (DSM41913), subsp. crystallogenes (NBRC16551), subsp. azalomyceticus (ATCC13810), and subsp. jinggangensis (Yu, Y. et al., (2005). Appl. Environ. Microbiol., 71(9), 5066-5076.), subsp. aabomyceticus (ATCC21449), and subsp. hialomyceticus (NBRC13946).
[0025] <2> Enhancement of bialaphos and / or L-glufosinate production
[0026] The bacterium of the present invention is a bacterium in which the production of bialaphos and / or L-glufosinate is enhanced by disrupting one or more genes contained in the lavendiol synthesis gene cluster or the actinoallolide A synthesis gene cluster, or by suppressing the expression of the genes. The Streptomyces bacterium of the present invention may have enhanced production of only one of bialaphos and L-glufosinate, and preferably has enhanced production of both bialaphos and L-glufosinate.
[0027] In Streptomyces bacteria, the biosynthesis of lavendiol and actinoalloride A is related to the genes constituting the lavendiol synthesis gene cluster and the actinoalloride synthesis gene cluster. Lavendiol and actinoallolide A are polyketides synthesized as secondary metabolites in Streptomyces bacteria. Lavendiol is also known as (3S,6E,8E,10E)-1,3-dihydroxy-4-methyl-6,8,10-dodecatrien-5-one, and actinoallolide A is also known as actinoallolide A. A is (5R,12R)-5-[(2R,3R,4R,8S,9R,10S)-3,9-dihydroxy-4,6,8,10-tetramethyl-11-oxotridec-6-en-2-yl]-12-ethyl-1-hydroxy-8,10-dimethyl-4,13-diox It is also called sabicyclo[8.2.1]tridec-7-ene-3,11-dione.
[0028] Lavendiol and actinoallolide A are biosynthesized by polyketide synthases (PKSs) using acetyl-CoA as a substrate in Streptomyces bacteria. Acetyl-CoA is not only a substrate for lavendiol and actinoallolide A, but also a substrate for actinoallolide A. , and is also required for the biosynthesis of bialaphos and L-glufosinate. Therefore, by disrupting one or more genes contained in the lavendiol synthesis gene cluster or the actinoallolide A synthesis gene cluster, or by suppressing the expression of the genes, the production of lavendiol and actinoallolide A can be suppressed. As a result, more acetyl-CoA is used for the production of bialaphos and L-glufosinate, and the metabolic flux is increased toward bialaphos. It is predicted that the synthesis of glycerol and L-glufosinate will be inclined toward increasing the productivity of bialaphos and L-glufosinate.
[0029] In the present invention, the "gene contained in the lavendiol synthesis gene cluster" is a polynucleotide having a base sequence of any one of SEQ ID NO: 1 and SEQ ID NO: 3 to 38 shown in Table 1, or a polynucleotide having a base sequence that hybridizes under stringent conditions to the complementary sequence thereof. In addition, the "gene contained in the actinoallolide A synthetic gene cluster" in the present invention is a polynucleotide having a base sequence of any one of SEQ ID NO: 2 and SEQ ID NO: 39 to 59 shown in Table 2, or a polynucleotide having a base sequence that hybridizes under stringent conditions to the complementary sequence thereof.
[0030] The genes shown in Table 1 are the genes that compose the gene cluster for lavendiol synthesis in bacteria belonging to Streptomyces viridochromogenes. The genes shown in Table 2 are the genes that compose the gene cluster for actinoalloride A synthesis in bacteria belonging to Streptomyces viridochromogenes.
[0031] [Table 1] In the table, "Accession number of the corresponding protein" indicates the Genbank accession number of the protein (or a partial sequence of the protein) encoded by the gene of the base sequence of each SEQ ID NO. The table shows the section number of each protein. In addition, in the table, "Protein function (estimated)" shows the protein function estimated from highly homologous proteins with known functions. In addition, the check marks in the table show those estimated to code for PKS.
[0032] [Table 2] In the table, "Accession number of the corresponding protein" indicates the Genbank accession number of the protein (or a partial sequence of the protein) encoded by the gene of the base sequence of each SEQ ID NO. The table shows the section number of each protein. In addition, in the table, "Protein function (estimated)" shows the protein function estimated from highly homologous proteins with known functions. In addition, the check marks in the table show those estimated to code for PKS.
[0033] In the present invention, the one or more genes contained in the lavendiol synthesis gene cluster or the actinoallolide A synthesis gene cluster whose expression is disrupted or suppressed preferably includes a gene encoding a polyketide synthesis enzyme. The "gene encoding polyketide synthase" in the lavendiol synthesis gene cluster is a polynucleotide having a base sequence of any one of SEQ ID NOs: 1 and 16 to 19, or a polynucleotide having a base sequence that hybridizes with its complementary sequence under stringent conditions and encodes a protein having polyketide synthase activity. The "gene encoding polyketide synthase" in the actinoallolide A synthesis gene cluster is a polynucleotide having a base sequence of any one of SEQ ID NOs: 2, 55, and 56, or a polynucleotide having a base sequence that hybridizes with its complementary sequence under stringent conditions and encodes a protein having polyketide synthase activity.
[0034] The gene encoding a polyketide synthase in the lavendiol synthesis gene cluster, which has been disrupted or whose expression has been suppressed, may be one or more of the polynucleotides containing any of the base sequences of SEQ ID NOs: 1 and 16 to 19, or may be all of the polynucleotides. Furthermore, the gene encoding a polyketide synthase in the actinoallolide A synthesis gene cluster that has been disrupted or whose expression has been suppressed may be one or more of the polynucleotides containing the base sequence of any of SEQ ID NOs: 2, 55, and 56, or may be all of the above polynucleotides.
[0035] The "lavendiol synthesis gene cluster or actinoallolide A synthesis gene cluster" of the present invention It is more preferable that the "one or more genes contained in the synthetic gene cluster" include the following polynucleotides (a) and / or (b): (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 or a polynucleotide having a nucleotide sequence which hybridizes under stringent conditions with its complementary sequence and encodes a protein having polyketide synthase activity; (b) a polynucleotide having a nucleotide sequence of SEQ ID NO: 2 or a polynucleotide having a nucleotide sequence that hybridizes under stringent conditions with its complementary sequence and encodes a protein having polyketide synthase activity;
[0036] "Stringent conditions" refer to conditions under which so-called specific hybrids are formed and non-specific hybrids are not formed. For example, two DNAs with high identity, preferably two DNAs with an identity of 80% or more, more preferably 90% or more, particularly preferably 95% or more, hybridize with each other, but two DNAs with lower identity do not hybridize. For example, the conditions include conditions under which the hybridization is performed once, preferably twice to 3 times, at a salt concentration and temperature corresponding to 60°C, 0.1×SSC, 0.1% SDS, more preferably 68°C, 0.1×SSC, 0.1% SDS. Examples of the condition include washing three times. That is, for example, the "gene contained in the lavendiol synthesis gene cluster" may have a base sequence having an identity of 80% or more, more preferably 90% or more, and particularly preferably 95% or more with the base sequence of any of the genes shown in Table 1. In addition, the "gene contained in the actinoallolide A synthesis gene cluster" may have a base sequence having an identity of 80% or more, more preferably 90% or more, and particularly preferably 95% or more with the base sequence of any of the genes shown in Table 2.
[0037] Furthermore, the "gene contained in the lavendiol synthesis gene cluster" of the present invention may have a base sequence containing one or several base substitutions, deletions, insertions, or additions in the base sequence of any of the genes shown in Table 1. The "gene contained in the actinoallolide A synthesis gene cluster" of the present invention may have a base sequence containing one or several base substitutions, deletions, insertions, or additions in the base sequence of any of the genes shown in Table 2. Here, one or several means, for example, 1 to 50, 1 to 30, 1 to 10, or 1 to 5. The "gene contained in the lavendiol synthesis gene cluster" of the present invention may be a partial sequence of any of the genes shown in Table 1 with the 5'-end and / or 3'-end deleted. The "gene contained in the actinoallolide A synthesis gene cluster" of the present invention may be a partial sequence of any of the genes shown in Table 2 with the 5'-end and / or 3'-end deleted.
[0038] "Polyketides" are compounds that use acetyl CoA as a substrate to produce lower molecular weight compounds such as acetate, propionate, and butyrate. The total number of compounds derived from β-keto carbon chains resulting from successive condensation reactions of carboxylic acid residues The term "polyketide synthase activity" refers to the activity of an enzyme that synthesizes a polyketide. The polyketide synthase activity can be measured by a known method, such as by mixing a substrate and a recombinant polyketide synthase to react with each other, and then quantifying the reaction product using LC-MS or the like. can.
[0039] The genes that are disrupted or whose expression is suppressed in the bacterium of the present invention may be only one or more genes contained in the lavendiol synthesis gene cluster or only one or more genes contained in the actinoallolide A synthesis gene cluster, or may be one or more genes contained in the lavendiol synthesis gene cluster and one or more genes contained in the actinoallolide A synthesis gene cluster. When one or more genes in the lavendiol synthesis gene cluster are disrupted or their expression is suppressed, all genes in the lavendiol synthesis gene cluster are When one or more genes in the actinoallolide A synthesis gene cluster are disrupted or the expression thereof is suppressed, all of the genes in the actinoallolide A synthesis gene cluster may be disrupted or the expression thereof is suppressed.
[0040] In the present invention, "one or more genes contained in the lavendiol synthesis gene cluster or the actinoalloride A synthesis gene cluster are destroyed" means that one or more genes contained in the lavendiol synthesis gene cluster or the actinoalloride A synthesis gene cluster are modified, and the original function of the gene is reduced or deleted. Methods for modifying genes include a method for deleting, substituting, or inserting all or part of the bases in the base sequence of the gene based on the base sequence information of the target gene, and a method for inducing mutation in the gene by UV irradiation or treatment with a mutagen such as nitrosoguanidine. The deletion, substitution, or insertion of all or part of the bases in the base sequence of the gene can be performed by homologous recombination technology, gene editing nuclease, zinc finger nuclease protein (ZFN), TAL effector nuclease (TALEN), or other suitable methods. Alternatively, this can be achieved by genome editing techniques using a combination of CRISPER-Cas9.
[0041] "All or part of the gene is deleted" means that all of the bases constituting the gene are deleted, or that, for example, 95% or more, preferably 90% or more, more preferably 80% or more, even more preferably 50% or more, even more preferably 30% or more, even more preferably 10% or more, and even more preferably 5% or more of the bases constituting the gene are deleted.
[0042] In the present invention, "the expression of one or more genes contained in the lavendiol synthesis gene cluster or the actinoalloride A synthesis gene cluster is suppressed" means that the expression level of one or more genes contained in the lavendiol synthesis gene cluster or the actinoalloride A synthesis gene cluster is reduced or the expression is lost. Methods for suppressing gene expression include a method using ribozymes or dCAS9 that are designed based on the base sequence information encoding the target gene and suppress the expression of the target gene. can be done.
[0043] Whether or not one or more genes in the lavendiol synthesis gene cluster or the actinoallolide A synthesis gene cluster have been disrupted or their expression has been suppressed can be confirmed by amplifying the target gene by PCR or by measuring the number of genes whose expression has been suppressed. The expression level of RNA and the amount of the protein encoded by the gene can be confirmed by known gene analysis techniques or protein analysis techniques.
[0044] "Enhanced production of bialaphos and / or L-glufosinate" may mean that the production amount of bialaphos and / or L-glufosinate is increased in a bacterium modified to disrupt one or more genes contained in the lavendiol synthesis gene cluster or the actinoallolide A synthesis gene cluster, or to suppress the expression of the genes, compared to an unmodified bacterium. Specifically, for example, it may mean that the modified bacterium produces and accumulates 1.1 times or more, 1.3 times or more, or 1.5 times or more of bialaphos and / or L-glufosinate in the medium and / or in the bacterial cells compared to an unmodified bacterium. The term "unmodified bacterium" may mean a bacterial strain that can be a control for the above comparison. "Unmodified bacterium" is also referred to as "unmodified strain" or "unmodified bacterial strain." Examples of unmodified bacterial strains include wild-type and parent strains of bacteria belonging to the genus Streptomyces (e.g., Streptomyces viridochromogenes). A specific example of an unmodified bacterial strain is Streptomyces viridochromogenes JCM4977.
[0045] The amount of bialaphos and / or L-glufosinate produced can be measured by a known method. For example, bialaphos and / or L-glufosinate accumulated in the medium or the bacterial cells can be measured by LC-MS / MS.
[0046] <3> The method for producing bialaphos and / or L-glufosinate of the present invention The method for producing bialaphos and / or L-glufosinate of the present invention comprises culturing the Streptomyces bacterium of the present invention in a culture medium to produce and accumulate bialaphos and / or L-glufosinate in the culture medium and / or the bacterial cells. Bialaphos and L-glufosinate can be produced in the form as described above. Bialaphos and L-glufosinate can be produced in particular in a free form, a salt thereof, or a mixture thereof. For example, salts such as sodium salt, potassium salt, and ammonium salt of bialaphos and L-glufosinate can be produced by the above method.
[0047] Furthermore, the method for producing bialaphos and / or L-glufosinate of the present invention includes a step of culturing the Streptomyces bacterium of the present invention in a culture medium to produce and accumulate bialaphos and / or L-glufosinate in the culture medium and / or the bacterial cells, and then recovering bialaphos and / or L-glufosinate from the culture medium and / or the bacterial cells. The method may optionally include a step of purifying bialaphos and / or L-glufosinate from the culture medium and / or the bacterial cells.
[0048] The cultivation of the bacteria and the optional recovery and purification of bialaphos and / or L-glufosinate from the medium or the like can be carried out in the same manner as in conventional fermentation methods for producing bialaphos and / or L-glufosinate using microorganisms. The culture medium may be a synthetic medium or a natural medium, such as a typical medium containing a carbon source, a nitrogen source, a sulfur source, a phosphorus source, inorganic ions, and other organic and inorganic components as necessary. As the carbon source, sugars such as glucose, sucrose, lactose, galactose, fructose, arabinose, maltose, xylose, trehalose, ribose, starch hydrolysates, and the like, alcohols such as ethanol, glycerol, mannitol, sorbitol, and the like, organic acids such as gluconic acid, fumaric acid, citric acid, malic acid, succinic acid, and the like, and fatty acids, and the like can be used. As the nitrogen source, inorganic ammonium salts such as ammonium sulfate, ammonium chloride, ammonium phosphate, and the like, organic nitrogen such as soybean hydrolysates, ammonia gas, and ammonia water, and the like can be used. In addition, peptone, yeast extract, meat extract, malt extract, corn steep liquor, etc. can also be used. The medium can contain one or more of these nitrogen sources. Examples of sulfur sources include ammonium sulfate, magnesium sulfate, iron sulfate, manganese sulfate, and the like. The medium may contain a phosphorus source in addition to the carbon source, nitrogen source, and sulfur source. Examples of phosphorus sources that can be used include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and phosphate polymers such as pyrophosphate. Vitamins such as vitamin B1, vitamin B2, vitamin B6, nicotinic acid, nicotinamide, and vitamin B12, as well as other necessary substances, such as adenine, nucleic acids such as RNA, amino acids, peptones, casamino acids, and organic nutrients such as yeast extract, may be present in appropriate amounts (even trace amounts). In addition to these, small amounts of calcium phosphate, iron ions, manganese ions, and the like may be added if necessary.
[0049] The culture can be carried out under conditions suitable for culturing the bacteria used in the method for producing bialaphos or L-glufosinate. For example, the culture can be carried out under aerobic conditions for 16 to 72 hours or 16 to 24 hours. The culture temperature during the culture can be controlled within the range of 28 to 45°C or 28 to 37°C. The pH can be adjusted between 5 and 8 or between 6 and 7.5. The pH can be adjusted by using an inorganic or organic acidic or alkaline substance, such as urea, calcium carbonate, or ammonia gas.
[0050] After the cultivation, bialaphos and L-glufosinate can be recovered from the culture medium. After the cultivation, bialaphos and L-glufosinate can be recovered from the bacterial cells. The cells are disrupted, solids such as the cells and cell disruption suspension (also referred to as cell debris) are removed to obtain a supernatant, and bialaphos or L-glufosinate can be recovered from the supernatant. The disruption of the cells can be carried out by a well-known method such as ultrasonic disruption using high-frequency sound waves. The removal of solids can be carried out by centrifugation or membrane filtration. Bialaphos or L-glufosinate can be recovered from the culture medium, supernatant, etc. by a conventional technique such as concentration, crystallization, ion exchange chromatography, medium- or high-pressure liquid chromatography, or a combination thereof.
[0051] The recovered bialaphos or L-glufosinate may contain, in addition to bialaphos or L-glufosinate, for example, bacterial cells, medium components, water, metabolic by-products of microorganisms, etc. Bialaphos acid may be purified to a desired degree. The purity of the recovered bialaphos or L-glufosinate is, for example, 50% or more, preferably 85% or more, particularly preferably 95% or more. good. EXAMPLES
[0052] Examples of the present invention will be described below, but the present invention is not limited to these examples.
[0053] [Example 1] (1) Primary selection of genes to be disrupted First, Streptomyces viridochromogenes ( S. viridochromogenes To predict the secondary metabolites that may be produced in Streptomyces viridochromogenes, we used the secondary metabolism gene cluster prediction algorithm antiSMASH based on the known genomic DNA information of Streptomyces viridochromogenes. Next, we performed gene expression analysis using a next-generation sequencer, and selected gene clusters with high average expression levels as targets for disruption.
[0054] (2) Secondary selection of genes to be disrupted From the gene clusters selected in the first stage, gene clusters in which expression of PKS, an enzyme responsible for the upstream reaction of the secondary metabolic pathway, was confirmed by gene expression analysis were selected for the second stage. Three gene clusters were selected by the selection: the actinoalloride A synthesis gene cluster, the lavendiol synthesis gene cluster, and the coelimycin synthesis gene cluster. The results of the first and second selections are shown in Table 3.
[0055] Of the three gene clusters selected in the second round, we were unable to obtain recombinants in which the kanamycin cassette was inserted into the targeted genomic region for the genes in the coelimycin gene cluster. Therefore, we evaluated the bialaphos productivity of each of the disruptant strains for the genes in the actinoallolide A gene cluster and the genes in the lavendiol gene cluster, as described below.
[0056] [Table 3] In the table, "compound" indicates the compound synthesized by the gene cluster, "number of genes" indicates the number of genes that make up the gene cluster, and "homology" indicates the homology of the base sequence to known gene clusters. "Y" indicates the gene cluster selected in the first selection, and "N" indicates the gene cluster selected in the first selection but not in the second selection. "Maximum expression level" indicates the expression level of the gene with the highest expression level in the gene cluster, and "average expression level" indicates the average expression level of all genes in the gene cluster. Conditions 1 to 4 indicate four samples with different culture conditions used in gene expression analysis.
[0057] (2) Construction of plasmid for gene disruption The plasmid for gene disruption was based on pKC1139 (Nova Lifetech, Catalog No. PVT6009). The base sequence of SEQ ID NO: 1 in the lavendiol synthase gene cluster and the base sequence of SEQ ID NO: 2 in the actinoallolide A synthesis gene cluster were targeted for disruption, and the genomic regions upstream and downstream of each base sequence were amplified by PCR using the primer sets shown in Table 4.
[0058] [Table 4] In the table, the base sequences are from left to right from the 5' end to the 3' end.
[0059] In addition, a kanamycin resistance gene cassette (SEQ ID NO: 60) containing the promoter region and terminator region shown in Table 5 was subjected to PCR using the primer set shown in Table 6. The EcoRI-SpeI fragments downstream of the base sequences of SEQ ID NOs: 1 and 2 to be disrupted were inserted into the EcoRI-XbaI gap of pKC1139. The resulting plasmids were amplified with EcoRI-XbaI. The plasmid was digested with EcoRI and XbaI, and an EcoRI-SpeI fragment of the upstream region of the base sequence to be disrupted was inserted into the plasmid, to construct a plasmid for gene disruption.
[0060] [Table 5] In the table, the base sequences are from left to right from the 5' end to the 3' end.
[0061] [Table 6] In the table, the base sequences are from left to right from the 5' end to the 3' end.
[0062] (3) Transformation of E. coli for conjugation Each of the constructed plasmids was used to transform E. coli by electroporation according to the following procedure. First, competent cells of the E. coli S17-1 strain were prepared by the following procedure. Streaking the glycerol stock of E. coli S17-1 on an LB plate, then incubating at 37°C for 16-20 hours. A single colony was obtained by inoculating the single colony into 2.5 mL of LB medium and incubated at 37 °C. The mixture was pre-cultured at 37°C, 200 rpm for 16 hours. 200 μl of the pre-culture was inoculated into 20 mL of LB medium and incubated at 37°C, 200 rpm for 16 hours at OD 600 The bacteria were harvested by centrifugation (4°C, 3000 xg, 10 min). Then, discard the supernatant, add 20 mL of ice-cold sterile water, and gently suspend the pellet with a pipette. After repeating the steps of collecting and washing the bacteria once more, the bacteria were collected again by centrifugation (4°C, 3000 xg, 10 min), the supernatant was discarded, and the pellet was gently suspended in 200 μl of ice-cold 10% glycerol using a pipette. 50 μl of this suspension was added to each tube (Eppendorf tube). Competent cells of the S17-1 strain were prepared by dispensing the cells into a culture flask (manufactured by Eppendorf).
[0063] The constructed plasmid (~2 μL) was added to the prepared competent cells and electroporated. The cells were transferred to a poration cell (Bio-Rad Laboratories, Inc.) and then left to stand on ice for 10 minutes. An electric pulse of 1.8 kV, 25 μF, and 200 Ω was applied, and 1 mL of LB medium was added. The cells were then harvested at 20,000 xg for 1 minute, the supernatant was removed, and the cells were resuspended in an appropriate amount of medium and plated on 2xYT agar medium containing 100 μg / mL kanamycin. The mixture was then smeared onto the soil and incubated overnight at 37°C.
[0064] (4) Transformation of Streptomyces bacteria The transformed E. coli was used to transform Streptomyces bacteria by conjugal transfer according to the following procedure. The E. coli S17-1 strain carrying the transformation plasmid obtained by the above culture was incubated at 100 μg / mL The bacteria was inoculated into 2 mL of LB medium containing 100 μg / mL kanamycin and precultured overnight at 37°C and 200 rpm. 100 μL of the preculture was inoculated into 10 mL of fresh LB medium (containing 100 μg / mL kanamycin) and the OD 600 The cells were cultured at 37°C and 200 rpm until the pH reached 0.4-0.8. The cells were harvested at 8000 xg for 10 minutes, the supernatant was discarded, and the harvested cells were suspended (washed) in 10 mL of LB medium by pipetting. The above process was repeated twice to remove the antibiotics contained in the culture medium. The collected bacterial pellet was then resuspended in 1 mL of LB medium. 500 μL of this E. coli suspension was then added to 500 mL of LB medium. Streptomyces viridochromogenes ( S. viridochromogenes ) JCM4977 stock Spores of a strain with an additional copy of the bialaphos synthase gene cluster (see reference example below) The mixture was mixed and centrifuged briefly. The spores were plated on 20 ml of ISP4 medium (2% by weight agar, 1% by weight Starch, 0.2% by weight calcium carbonate, 0.2% by weight ammonium sulfate, 0.1% by weight phosphorus The actinomycetes were plated on a medium containing 0.1% by weight dipotassium hydrogen carbonate, 0.1% by weight magnesium sulfate heptahydrate, 0.1% by weight sodium chloride, 0.1% by weight yeast extract, 0.0001% by weight iron(II) sulfate heptahydrate, 0.0001% by weight manganese chloride heptahydrate, and 0.0001% by weight zinc sulfate heptahydrate, and incubated at 28°C for two weeks. It was obtained by culturing to a certain extent. After the above centrifugation, the supernatant was discarded, leaving about 50 μL, and the bacterial pellet was resuspended in the remaining supernatant, after which a dilution series was prepared with sterile water, and 100 μL was applied to 20 ml of ISP4 plate medium and cultured overnight at 28° C. 0.5 mg nalidixic acid and 10 ml of 100 mg / mL kanamycin were added to 1 ml of sterile water, which was then layered on the medium and cultured at 28° C. for an additional 3 to 5 days to obtain each transformant of Streptomyces bacteria.
[0065] (5) Selection of gene-disrupted actinomycetes The obtained transformants were confirmed by colony PCR. In the colony PCR, a set of primers designed in a genomic region outside the homologous region and a primer in the kanamycin resistance gene region was used. The primer set used is shown in Table 7.
[0066] [Table 7] In the table, the base sequences are from left to right from the 5' end to the 3' end.
[0067] (6) Jar culture of actinomycetes 150 ml of YS medium (1% by weight soluble starch, 0.2% by weight yeast extract) was placed in a 500 ml Each disruptant and negative control were inoculated into a flask with a funnel and pre-cultured (28°C, 135 rpm) for 2 days. Then, 10 ml of the pre-culture solution was added to a 500 ml flask containing 150 ml of MYG medium (1% by weight malt extract, 0.4% by weight yeast extract, 0.4% by weight glucose). The bacteria were inoculated into a flask with a full flask and pre-cultured (28°C, 135 rpm) for 1 day. 1 ml was added to 1 L of jar culture medium (0.4 wt% glucose, 1.5 wt% malt extract, 1.2 wt% yeast extract, 0.0001 wt% CoCl 2 6H 2 O) and incubated at 28 °C in a 2 L jar fermenter. The culture was carried out for 12 days under the conditions of H 7.4 and aeration of 1slpm (1L / min). The concentration was controlled at 0.5 ppm. In addition, on the 4th, 7th and 11th days of the culture, a supplemented medium (10% by weight of glucose) was added. The culture medium was supplemented with 100 ml of a 5% yeast extract (5% by weight). (Example) was used as a negative control. The culture medium was sampled on days 4, 6, 7, 8, 11, and 12, and the dry cell weight and glucose concentration were measured by standard methods. In addition, the bialaphos concentration in the culture medium sampled on day 12 was measured by LC-MS / MS.
[0068] (7) Results The productivity of bialaphos and L-glufosinate of each disruption strain obtained is shown in Figures 1 and 2. As a result, it was confirmed that each disruption strain had improved productivity compared to the negative control. As shown in Figure 3, the bacterial growth of each disruption strain obtained was comparable to that of the negative control, but as shown in Figure 4, glucose consumption was slower, which suggests that nutrient sources such as glucose were efficiently used for bialaphos production.
[0069] [Reference example: Creation of a strain with an additional copy of the bialaphos biosynthetic enzyme gene cluster] Streptomyces viridochromogenes JCM4977 was cloned with the bialaphos synthase gene. A strain with one additional copy of star was created by the following procedure. It is known that B. viridochromogenes has a bialaphos synthesis gene cluster shown in FIG. 5. The gene cluster contains the 5'-terminal From the side, the phpA gene, the phsB gene, the phpB gene, the phsC gene, the pmi gene, and the phpC gene. phpD gene, phpE gene, ppm gene, ppd gene, phpF gene, phpG gene, phpH gene, phpI gene, phpJ gene, phpK gene, pms gene, phsA gene, pat gene, dea It is known that the phpA gene, the phpL gene, the phpM gene, the phpN gene, and the phpR gene exist (Blodgett et al. 2016, J Antibiot (Tokyo). 69, 15-25).
[0070] (1) Construction of plasmid for gene transfer The plasmid for gene transfer was based on pSET152 (Creative Biogene, Cat. No. OVT2796). The genome DNA of Streptomyces viridochromogenes JCM4977 strain was used as a template to construct the vector. Each DNA fragment of the Sq1 to Sq6 and F3 regions of the bialaphos synthase gene cluster was The primer set shown in Table 8 was used for amplification by PCR. First, the obtained XbaI-EcoRV fragment of F3 was inserted into the XbaI-EcoRV gap of pSET152 to construct a plasmid into which F3 (F3 in FIG. 5) was introduced. Next, the NheI-SbfI fragment of Sq6 and the SbfI-EcoRV fragment of F3 were inserted into the XbaI-EcoRV gap of pSET152 to construct a plasmid into which Sq6F3 (Sq6F3 in FIG. 5) was introduced. Next, the MunI-SpeI fragment of Sq5 was inserted into the EcoRI-XbaI gap of the plasmid into which Sq6F3 was introduced to construct a plasmid into which Sq5-6F3 (Sq5-6F3 in FIG. 5) was introduced. Similarly, the MunI-SpeI fragment of Sq4, the MunI-SpeI fragment of Sq3, the MunI-SpeI fragment of Sq2, and the MunI-SpeI fragment of Sq1 were inserted, respectively, and the resulting vectors were shown in FIG. The plasmid in which the full length of the bialaphos synthase gene cluster was introduced into pSET152. was constructed.
[0071] [Table 8]
[0072] The base sequences of the primer sets shown in Table 8 are shown in Table 9.
[0073] [Table 9] In the table, the base sequences are from left to right from the 5' end to the 3' end.
[0074] (2) Transformation of E. coli for conjugation Escherichia coli was transformed with the constructed plasmid in the same manner as in "(3) Transformation of Escherichia coli for conjugation" in Example 1, except that 100 μg / mL apramycin was used as the antibiotic.
[0075] (3) Transformation of Streptomyces bacteria The Streptomyces bacterium to be transformed was Streptomyces viridochromogenes ( S. viridochromogenes The JCM4977 strain was used, and 100 μg / mL apramycin was used as an antibiotic for the culture of E. coli S17-1 strain, and 0.5 mg nalidixic acid and 10 μl of 100 mg / mL apramycin in 1 ml of sterile water were used for the selection of Streptomyces viridochromogenes. A strain containing an additional copy of the bialaphos biosynthetic enzyme gene cluster was obtained by transforming Streptomyces bacteria using the same procedure as in “(4) Transformation of Streptomyces bacteria” in Example 1, except for the addition of ramycin.
Claims
1. A bacterium belonging to the genus Streptomyces, A bacterium in which production of bialaphos and / or L-glufosinate is enhanced by disrupting one or more genes contained in the lavendiol synthesis gene cluster or the actinoalloride A synthesis gene cluster, or by suppressing the expression of the genes.
2. The bacterium of claim 1 , wherein the one or more genes include a gene encoding a polyketide synthase.
3. The bacterium according to claim 1 , wherein the one or more genes comprise the following polynucleotides (a) and / or (b): (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 or a polynucleotide having a nucleotide sequence which hybridizes under stringent conditions to its complementary sequence and encodes a protein having polyketide synthase activity; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2 or a polynucleotide having a nucleotide sequence which hybridizes under stringent conditions to its complementary sequence and encodes a protein having polyketide synthase activity;
4. 2. The bacterium according to claim 1, which is a bacterium belonging to Streptomyces viridochromogenes or Streptomyces hygroscopicus.
5. A method for producing bialaphos and / or L-glufosinate, comprising: A production method comprising culturing the bacterium according to any one of claims 1 to 4 in a culture medium to produce and accumulate bialaphos and / or L-glufosinate in the culture medium and / or the bacterial cells.
